Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next?

Mainz Biomed NV (NASDAQ:MYNZ)’s stock price fell 5.8% during mid-day trading on Friday . The company traded as low as $0.92 and last traded at $0.9990. 283,999 shares traded hands during trading, a decline of 68% from the average session volume of 897,663 shares. The stock had previously closed at $1.06.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Mainz Biomed currently has a consensus rating of “Hold” and an average target price of $14.00.

Mainz Biomed Trading Down 5.8%

The firm’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $1.70. The stock has a market cap of $5.40 million, a P/E ratio of -0.02 and a beta of 0.25. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44.

Institutional Trading of Mainz Biomed

An institutional investor recently raised its position in Mainz Biomed stock. Armistice Capital LLC grew its holdings in shares of Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 285,000 shares of the company’s stock after acquiring an additional 88,400 shares during the quarter. Armistice Capital LLC owned about 6.23% of Mainz Biomed worth $402,000 as of its most recent SEC filing.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.